|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||30.97 - 31.01|
|52-week range||25.87 - 32.10|
|Beta (5Y monthly)||1.24|
|PE ratio (TTM)||25.88|
|Forward dividend & yield||0.44 (1.37%)|
|Ex-dividend date||10 May 2021|
|1y target est||N/A|
Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc. today announced topline data from the ACCOLADE clinical study, the largest, randomized, blinded, placebo-controlled phase-II trial in the ultra-rare kidney disease C3 glomerulopathy (C3G) to date, which evaluated avacopan for the treatment of that disorder. Avacopan is a first-in-class, orally-administered selective inhibitor of the complement C5a receptor.